<PAGE> 1
U. S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
Annual report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
For the fiscal year ended December 31, 1996
Commission file number: 1-13738
PSYCHEMEDICS CORPORATION
(exact name of registrant as specified in its charter)
Delaware 58-1701987
- ------------------------------- ------------------------------------
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
1280 Massachusetts Ave., Cambridge, MA 02138
- ----------------------------------------- ------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: 617-868-7455
Securities registered pursuant to Section 12(b) of the Act:
Common Stock, $.005 Par Value American Stock Exchange
- ----------------------------- ----------------------------------------
(Title of class) (name of each exchange on which registered)
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
YES [X] NO [ ]
Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-B is not contained herein and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K [ ]
On March 14, 1997 the aggregate market value of the voting stock held by
non-affiliates of the registrant was $ 91,553,934 and 21,827,791 shares of
Common Stock, $.005 par value, were outstanding at such date.
DOCUMENTS INCORPORATED BY REFERENCE
-----------------------------------
Part III - Portions of the Registrant's Proxy Statement relative to the 1997
Annual Meeting of Stockholders to be held on May 8, 1997.
<PAGE> 2
PART I
Item 1. Business
General
Psychemedics Corporation ("the Company") is a Delaware corporation organized on
September 24, 1986 to provide testing services for the detection of abused
substances through the analysis of hair samples. The Company's testing methods
utilize a patented technology for performing immunoassays on enzymatically
dissolved hair samples with confirmation testing by gas chromatography/mass
spectrometry ("GC/MS").
The Company's first application of its patented technology is a testing service
which screens for the presence of certain drugs of abuse in hair. The
application of radioimmunoassay procedures using hair differs from the more
widely used application of radioimmunoassay procedures using urine samples. The
Company's tests provide quantitative information which indicates the approximate
amount of drug ingested as well as historical data which can show a pattern of
individual drug use over a period of time. This information is useful to
employers in both applicant and employee testing, to physicians, treatment
professionals, law enforcement agencies, to the insurance industry, to other
individuals and entities engaged in any business where drug use is an issue, and
to parents concerned about drug use by their children. The Company provides
commercial testing and confirmation by GC/MS using industry accepted practices
for cocaine, marijuana, PCP, methamphetamine, and opiates. In addition, the
Company has developed a test for methadone for use in the treatment industry.
Testing services are currently performed at the Company's laboratory at 5832
Uplander Way, Culver City, California. The Company's services are marketed under
the name RIAH, (Radioimmunoassay of Hair), a registered service mark.
Development of Radioimmunoassay of Hair
The application of special radioimmunoassay procedures to the analysis of hair
was initially developed in 1978 by the founders of the Company, Annette
Baumgartner and Werner A. Baumgartner, Ph.D. The Baumgartners demonstrated that
when certain chemical substances enter the bloodstream, the blood carries them
to the hair where they become "entrapped" in the protein matrix in amounts
roughly proportional to the amount ingested. The Company's drugs of abuse
testing procedure involves washing the hair sample to clean it of surface
contaminants and then subjecting the cleaned hair sample to the Company's unique
proprietary process which involves the direct analysis of liquefied hair samples
by radioimmunoassay procedures utilizing special reagents and antibodies. The
antibodies detect the presence of a specific drug or metabolite in the liquefied
hair sample by reacting with the drug present in the sample solution and an
added radioactive analog of the drug. The resulting antibody-drug complex is
precipitated and analyzed. The amount of drug present in the sample is inversely
proportional to the amount of radioactive analog in the precipitate. Depending
upon both the length of hair and the hair growth rate (hair grows approximately
1.3 centimeters per month), the Company is able to provide historical
information on drug use by the person from whom the sample was obtained. Another
testing option involves sectional analysis of the hair sample. In this
procedure, the hair is sectioned lengthwise to approximately correspond to
certain time periods. The sections are
2
<PAGE> 3
then labeled by time period, which allows the Company to provide trend
information on drug use. When quantitative results of this test are reported and
compared to dose correlation graphs, information is provided about the
individual's approximate drug usage during the period being tested.
Validation of the Company's Proprietary Testing Method
The process of analyzing human hair for the presence of drugs using the
Company's patented method has been the subject of over fifty scientific field
studies. Results from the studies that have been published or accepted for
publication in scientific journals are generally favorable to the Company's
technology. These studies were performed with the following organizations:
Citizens for a Better Community Court, Columbia University, Koba Associates-DC
Initiative, Harvard Cocaine Recovery Project, Hutzel Hospital, ISA Associates
(Interscience America)-NIDA Workplace Study, University of California-Sleep
State Organization, Maternal/Child Substance Abuse Project, Matrix Center,
National Public Services Research Institute, Narcotic and Drug Research
Institute, San Diego State University-Chemical Dependency Center, Spectrum Inc.,
Stapleford Centre (London), Task Force on Violent Crime (Cleveland, Ohio);
University of Miami-Department of Psychiatry, University of Miami-Division of
Neonatology, University of South Florida-Operation Par Inc., University of
Washington, VA Medical Center-Georgia, U.S. Probation Parole-Santa Ana. The
above studies include research in the following areas: prenatal, treatment
evaluation, workplace drug use, the criminal justice system and epidemiology.
Many of the studies have been funded by the National Institute of Justice or the
National Institute on Drug Abuse ("NIDA"). Over 300 research articles written by
independent researchers have been published supporting the general validity and
usefulness of hair analysis.
An additional independent evaluation of the technology, favorable to the
Company's services, has been performed by submission of blind samples by Dr.
Robert DuPont, President of the Institute of Behavior and Health, Inc., the
first Director of the National Institute on Drug Abuse and presently Chairman of
the Company's Scientific Advisory Board. Some of the Company's customers have
also completed their own testing to validate the Company's proprietary hair
testing method as a prelude to utilizing the Company's services. These studies
have consistently confirmed the Company's superior detection rate. When the
results from utilizing the Company's patented hair testing method were compared
to urine results in side-by-side evaluations, 5 to 10 times as many drug abusers
were accurately identified with the Company's proprietary method. In addition to
these studies, the Company is now performing testing for over 750 clients.
During 1996, the Company's patented method was utilized in a number of important
research application studies. In a study funded by the White House Office of
National Drug Control Policy (the Drug Czar's office) in 1996, hair analysis was
used to assess levels of drug use in hard-core drug abusers. The National
Institute of Justice sponsored an investigation using hair analysis to determine
the extent of drug use among prison inmates. Additional research studies were
conducted at Texas Christian University, Texas A & M, UCLA, University of
Pennsylvania and the University of South Florida. These studies investigated
drug abuse among juvenile delinquents, homeless individuals, HIV patients and
pregnant women.
3
<PAGE> 4
Advantages of Using the Company's Patented Method
The Company asserts that hair testing using its patented method confers
substantive advantages relative to existing means of drug detection through
urinalysis. Although urinalysis testing can provide accurate drug use
information, the scope of the information is short-term and is generally limited
to the type of drug ingested within a few days of the test. Studies published in
many scientific publications including NIDA Research Monograph and the Journal
of Forensic Sciences have indicated that cocaine, PCP, opiates, and
methamphetamine disappear from urine within 72 to 96 hours of use, although
marijuana may take a week or more.
In contrast to urinalysis testing, hair testing using the Company's patented
method provides long-term historical drug use information resulting in a
significantly wider "window of detection." This "window" may be three months or
longer depending on the length of the hair sample. The Company's standard test
offering, however, uses a 3.9 centimeter length cut close to the scalp;
therefore, it measures use for approximately the previous 90 days.
This wider window of detection enhances the detection efficiency of hair
analysis making it particularly useful in pre-employment testing. Hair testing
not only identifies more drug users, but also uncovers patterns and severity of
drug use, information most helpful in determining the scope of an individual's
involvement with drugs and serves as a deterrent against the use of drugs. Hair
testing using the Company's patented method greatly reduces the incidence of
"false negatives" associated with evasive measures typically encountered with
urinalysis testing. Urinalysis test results are impacted adversely by excessive
fluid intake prior to testing as well as adulteration of the sample. Moreover, a
drug user who abstains from use for a few days prior to urinalysis testing can
usually escape detection. Hair testing is effectively free of these problems as
it cannot be thwarted by evasive measures typically encountered with urinalysis
testing. It is also attractive to customers since sample collection is typically
performed under close supervision yet is less intrusive and embarrassing for
test subjects.
Hair testing using the Company's patented method (with GC/MS confirmation)
further reduces the prospects of error in conducting drug detection tests.
Urinalysis testing is more susceptible to problems such as "evidentiary false
positives" resulting from passive drug exposure (e.g. poppy seeds.) In the event
a positive urinalysis test result is challenged based on passive exposure, the
only remedy is a newly collected sample. Depending on the drug usage of the
forewarned individual prior to the date of the newly collected sample, a re-test
may yield a negative result when using urinalysis testing because of temporary
abstention. In contrast, when the Company's hair testing method is offered on a
repeat hair sample the individual suspected of drug use cannot as easily affect
the results because historical drug use data remain locked in the hair fiber.
Disadvantages of Hair Testing
There are some disadvantages of hair testing as compared to drug detection
through urinalysis. Because hair starts growing below the skin surface, drug
ingestion evidence does not appear in hair above the scalp until five to seven
days after use.
4
<PAGE> 5
Thus, hair testing is not suitable for use in "for cause" testing such as is
done in connection with an accident investigation. It does, however, provide a
drug history which can complement urinalysis information in "for cause" testing.
Currently, radioimmunoassay testing using hair samples under the Company's
patented method is only practiced by Psychemedics Corporation. The absence of
widespread familiarity and use of hair testing may adversely impact the
Company's revenue growth.
The Company's prices for its tests are generally somewhat higher than prices for
comparable tests using urinalysis, but the Company believes that its superior
detection rates provide more value to the customer. This pricing policy could,
however, adversely impact the growth of the Company's sales volume.
Patents
In December 1987, Dr. Werner A. Baumgartner, the Company's founder and Director
of Research and Development, with the assistance of the Company's patent
counsel, filed the first in a series of patent applications in the U.S. Patent
and Trademark Office on his inventions relating to radioimmunoassay using hair.
In 1994, U.S. Patent No. 5,324,642 (the "642 Patent") was issued to the Company.
This patent pertains to the universal drug extraction procedure and immunoassay
technology for the detection of drugs in hair specimens. In 1995, the Company
was granted an additional patent covering Dr. Baumgartner's inventions
pertaining to the immuno chemical screening assay for marijuana, which is the
most difficult drug to detect. Dr. Baumgartner has continued his research, and
the Company has pending two additional patent applications in the U.S. Patent
and Trademark Office with respect to his inventions relating to procedures using
hair. The Company believes that additional patents will be granted as a result
of Dr. Baumgartner's pending patent applications although there can be no
assurance that any such additional patents will be granted.
Pursuant to an agreement dated January 1987, Werner A. Baumgartner and Annette
Baumgartner granted to the Company an exclusive royalty-free worldwide license
of all of their rights in and to their inventions relating to radioimmunoassay
using hair.
Most of Dr. Baumgartner's research on the inventions covered by the 642 Patent
was conducted while he was employed by the Veteran's Administration Hospital
("VA"). Dr. Baumgartner has, therefore, also granted to the U.S. government, for
all Governmental purposes, a nonexclusive, irrevocable, royalty-free license to
use the basic invention during the term of the patent with respect to such
invention.
Certain aspects of the Company's hair analysis method are based on trade secrets
owned by the Company. The Company's ability to protect the confidentiality of
these trade secrets is dependent upon the Company's internal safeguards and upon
the laws protecting trade secrets and unfair competition. In the event that
patent protection or protection under the laws of trade secrets were not
sufficient and the Company's competitors succeeded in duplicating the Company's
products, the Company's business could be materially adversely affected.
5
<PAGE> 6
Target Markets
1. Industry
The Company has focused its primary marketing efforts on the private sector. The
Company believes that the market for job applicant and employee testing will
yield the most immediate beneficial impact to the business of the Company and
assist in establishing a regular client base.
The number of businesses using drug testing to screen job applicants and
employees has increased significantly in the last nine years. The 1996 American
Management Association (AMA) survey indicated that 81% of surveyed firms were
engaged in some form of drug testing, a 277% increase since the initial AMA
survey in 1987. The prevalence of drug screening programs reflects a growing
concern that drug use contributes to employee health problems and costs
(increased absenteeism, reduced productivity, etc.) and in certain industries,
safety hazards. It has been estimated that the cost to industry in terms of
health care costs and lost productivity is at least $60 billion annually.
The principal criticism of employee drug screening programs centers on the
effectiveness of the testing program. Most private sector screening programs use
urinalysis. Such programs are susceptible to evasive maneuvers and the inability
to obtain identical repeat samples in the event of a challenged result.
Moreover, many employers, to accommodate concerns of their employees and to
avoid infringement of employee privacy rights, conduct their programs on a
pre-announced schedule, thereby providing an opportunity for many drug users to
abstain in order to escape detection.
The Company presents its patented hair analysis method to potential clients as a
better technology well suited to employer needs. Field studies and actual client
results support the accuracy and effectiveness of the Company's patented
technology and its ability to detect even casual drug use. The historical aspect
of the Company's patented method as well as the Company's ability to provide
correlation of the measured drug with approximate amount of ingestion, furnish
an employer with greater flexibility in assessing the scope of an applicant's or
an employee's drug problem.
The Company provides clients confirmation of positive results through GC/MS. The
use of GC/MS is an industry accepted practice used to confirm positive drug test
results of an initial screen. In an employment setting, GC/MS confirmation is
typically used prior to the taking of any disciplinary action against an
employee. The Company offers its clients a five-drug screen with GC/MS
confirmation of cocaine, PCP, marijuana, methamphetamine, and opiates.
2. Home Use
In 1995, the Company began marketing "PDT-90",, its hair testing service to
parents concerned about drug use by their children. It allows parents to collect
a small sample from their child in the privacy of the home and have it tested
for drugs of abuse by the Company. The PDT-90 testing service uses the same
patented method that is used with the Company's workplace testing service. The
Company commenced a marketing campaign in the third quarter of 1995 for the new
service.
6
<PAGE> 7
3. Medical
The Company has developed a medical market for its proprietary hair testing
method consisting mostly of testing services for use by treatment professionals
for drug recovery programs and prenatal care.
In the drug treatment area, the Company's patented method can be used by
treatment professionals to obtain background information on drug use,
information most critical in structuring an individual's recovery program. Under
traditional drug detection tests, this information is obtained from
self-reporting, an approach generally deemed unreliable for various reasons,
including reluctance to discuss the nature of one's drug habit, memory failure,
and unknown substance purity. As a follow-up to a rehabilitation process, the
Company's patented method provides additional support by generating feedback to
individual physicians, psychiatrists and therapists on the success of their
methods. The utility of the Company's technology in monitoring recovery after
discharge from employee assistance programs has been validated by the Company's
customers. The Company's recently developed methadone test can also assist
treatment professionals in their treatment efforts.
The Company has engaged in, and continues to engage in, studies supporting the
utility of its patented hair analysis method in the evaluation of drug use
during pregnancy and the corresponding treatment of newborns. Studies are under
way at University of Pennsylvania, Hutzel Hospital, University of Washington,
Columbia University, University of Miami, National Public Services Research
Institute, University of California-Sleep State Organization and Maternal/Child
Substance Abuse Project. The Company expects that these cost-benefit and
application studies will demonstrate the utility of its proprietary screen in
the prenatal market.
Sales and Marketing
The Company markets its corporate drug testing services primarily through its
own direct sales force. The Company's in-house efforts are supplemented by a
limited network of independent sales representatives who are thoroughly trained
by the Company. The Company markets PDT-90, its home testing drug service,
through a toll-free number. For both its business-to-business and consumer
direct services, the Company has undertaken an integrated marketing campaign to
enhance the market presence within each respective segment.
Competition
The Company competes directly with numerous commercial laboratories which test
for drugs through urinalysis testing. Most of these laboratories, such as
Laboratory Corporation of America, SmithKline Beecham Clinical Laboratories and
Corning Clinical Laboratories, Inc. have substantially greater financial
resources, market identity, marketing organizations, facilities, and numbers of
personnel than the Company. The Company has been steadily increasing its base of
corporate customers and believes that future success with new customers is
dependent on the Company's ability to communicate the advantages of implementing
a drug program utilizing the Company's patented hair analysis method.
The Company's ability to compete is also a function of pricing. The Company's
prices for its tests are generally somewhat higher than prices for comparable
tests using urinalysis. However, the Company believes that its superior
detection rates,
7
<PAGE> 8
coupled with the customer's ability to test less frequently due to hair
testing's wider window of detection (approximately 90 days verses approximately
three days with urinalysis) provide more value to the customer. This pricing
policy could, however, lead to slower sales growth for the Company.
The Company is not aware of any other laboratories with a hair analysis
technology that is comparable in effectiveness to the Company's proprietary
procedures. The Company is aware of two laboratories which operate in certain
limited employment testing markets and which purport to test hair samples using
a method, which the Company presumes, includes the use of a form of immunoassay
procedures. The Company, however, does not believe that effective immunoassay
testing of hair samples is currently feasible on a commercial basis without
using the Company's unique patented method.
Government Regulation
The Company is licensed as a Clinical Laboratory by the State of California as
well as certain other states. All tests are performed according to the standards
established by the Clinical Laboratories Improvement Act and the College of
American Pathologists. Presently there are no other regulations required for the
operation of a clinical laboratory in the State of California.
A substantial number of states regulate drug testing. The scope and nature of
such regulation varies greatly from state to state. In some states, a clinical
laboratory such as the Company is required to satisfy certain requirements as a
precondition to the laboratory's certification or right to perform drug testing
services with respect to specimens obtained in such state. The laws or
regulations in other states, in some instances, limit testing to certain
matrixes ("matrix" refers to the substance, blood, urine, hair, etc., which is
tested for the presence of drugs) which in two states excludes hair. The Company
seeks, through participation in the legislative and regulatory process, to
educate the legislative and regulatory agencies of those few states whose
statutes have been interpreted to not include the testing of hair.
In August 1995, the United States Food and Drug Administration ("FDA") issued a
Warning Letter to the Company pertaining to PDT-90, the drug testing service
which the Company introduced in July 1995 as a testing service for parents
concerned about drug use by their children. The FDA claimed that the collection
envelope the Company distributed as part of the PDT-90 testing service
constituted a "medical device" under the Federal Food Drug and Cosmetic Act, as
amended (the "FDC Act"), and that, because the Company did not seek the approval
or permission of the FDA to market the envelope, it was therefore adulterated
and misbranded under the FDC Act.
In its response, the Company stated its position that the collection envelope is
not a medical device under the FDC Act. However, in order to expeditiously
resolve the matter with the FDA, the Company submitted a 510(k) premarket
notification to the FDA on September 27, 1995 seeking a determination from the
FDA that the collection envelope is substantially equivalent to collection
envelopes which previously received 510(k) premarket clearance and were
currently being commercially marketed. In November 1995, the FDA issued a "Not
Substantially Equivalent" ("NSE") determination in response to the Company's
510(k) submission and classified PDT-90 as a Class III device under the FDC Act.
8
<PAGE> 9
In December 1995, the Company filed suit against the FDA in the United States
Court of Appeals for the First Circuit seeking to overturn the FDA's NSE
determination. In March 1996, the FDA agreed to withdraw the Warning Letter and
the NSE determination in exchange for the Company's dismissal of its suit
against the FDA. The FDA also confirmed its decision not to actively regulate
PDT-90 and not to pursue enforcement action on any of the grounds contemplated
in the Warning Letter.
On February 6, 1997, the FDA announced a new agency proposal to companies that
make "drugs of abuse test systems". Under the proposal, companies engaged in the
business of testing for drugs of abuse using immunoassay testing procedures
previously recognized by the FDA would be able to market their test systems
without pre-market approval or clearance by the FDA so long as the tests are
conducted at certain approved laboratories and certain labeling and product
information procedures are followed. To date, the FDA has recognized immunoassay
testing procedures which involve the use of urine and sweat as the test sample
in certain applications. Under the FDA proposal, companies engaged in the
business of testing for drugs of abuse using samples other than those previously
recognized would effectively be prohibited from operating without FDA approval
or clearance. Such companies would be required to submit their test to the FDA
for recognition. The FDA's February 1997 announcement states that it intends to
implement the proposed new policy through notice and comment rulemaking. The
proposal includes a transitional period of approximately two years in order for
companies not currently in compliance with the proposed requirements to obtain
the necessary data they need for submission to the FDA. The Company believes
that its proprietary method of detecting drugs of abuse using hair samples is
accurate and reliable and should, therefore, be recognized if necessary.
However, the Company maintains that the FDA lacks statutory authority to
regulate its drug testing service. There is a risk that, under regulations which
may hereafter be adopted in light of the FDA's proposal, an application by the
Company for recognition of the Company's proprietary hair testing technology
could be denied, in which event, if upheld on appeal, the Company's business
would be materially adversely affected.
Scientific Advisory Board
The Company has established a Scientific Advisory Board which consults with
management of the Company to examine and evaluate the progress of the Company's
research and development activities, to promote independent validation studies
of the Company's patented hair analysis method technology, and to assist in
accelerating acceptance of the technology in both the public and private
sectors. Members of the Scientific Advisory Board are compensated at the rate of
$1,000 per day for each meeting attended plus reimbursement for out-of-pocket
expenses. The Chairman of the Scientific Advisory Board is Dr. Robert DuPont.
Dr. DuPont's career has included numerous positions in the psychiatric and
substance abuse field, including Director, Special Action Office for Drug Abuse
Prevention - The White House; the first Director, National Institute on Drug
Abuse; President, American Council for Drug Education; and President, Phobia
Society of America. Dr. DuPont has received several national awards and
presently serves as President: Institute for
9
<PAGE> 10
Behavior and Health, Inc.; Vice President, Bensinger, DuPont and Associates, a
national drug and alcohol abuse consulting firm; and he maintains a private
practice in psychiatry. Dr. DuPont has also been granted options to acquire
shares of the Company's common stock. Other members of the Scientific Advisory
Board are Edward C. Senay, M.D., a Professor in the Department of Psychiatry at
the University of Chicago, and Arthur McBay, Ph.D., a Forensic Toxicologist and
former Professor of Pharmacy at the University of North Carolina.
Research and Development
The Company is continuously engaged in research and development activities.
During the years ended December 31, 1996, 1995 and 1994, $413,693, $436,385 and
$406,345, respectively, were expended for research and development. The Company
continues to perform research activities to develop new products and services
utilizing the Company's proprietary technology. Additional research using the
Company's proprietary technology is being conducted by outside research
organizations through government-funded studies.
The Company's research includes "controlled studies" to determine the advantages
of hair testing in the medical, forensic and criminal justice markets. The
Company has also furnished technical assistance to several distinguished
independent researchers whose studies have been funded through government
grants. Many such studies are currently in progress. The Company continues to
conduct its own research toward the development of new inventions, services and
products derived from the Company's patented technology.
Sources and Availability of Raw Materials
Since its inception, the Company has purchased raw materials for its laboratory
services from outside suppliers. The most critical of these raw materials are
the radio-labeled drugs which the Company purchases from a single supplier,
although other supplies of radio-labeled drugs exist. If suitable radio-labeled
drugs were to become unavailable, or available only at prohibitive cost, the
Company would be required to produce its own radio-chemical supplies, although
other suppliers of radio-labeled drugs exist. The Company estimates that it
would have to expend approximately $400,000 for capital additions to produce its
own supply. Thereafter, direct costs for such raw materials would likely
decrease.
Principal Customer
The Company's major customer, Blockbuster Entertainment Group ("Blockbuster"), a
division of Viacom, Inc., accounted for approximately 19% of the Company's drug
testing sample volume and approximately 15% of the Company's revenue during the
year ended December 31, 1996. The Company's agreement with Blockbuster is
terminable at will by either party and the loss of Blockbuster as a customer
could have a material adverse effect on the Company. However, the Company
believes that its relations with Blockbuster are satisfactory.
Employees
As of December 31, 1996, the Company had 71 full-time equivalent employees, of
which four full-time employees were in research and development. None of the
Company's employees is subject to a collective bargaining agreement.
10
<PAGE> 11
Item 2. Properties.
The Company maintains its corporate office and northeast sales office at 1280
Massachusetts Avenue, Cambridge, Massachusetts; the office is leased through
September 1998.
The Company leases 18,000 square feet of space in Culver City, California, for
sales, customer service and laboratory purposes. This facility is leased through
December 31, 1997 with an option to renew for an additional five years.
Item 3. Legal Proceedings.
The Company's recent dispute with the Food and Drug Administration is described
above under Business Government Regulation. The Company is involved in various
other suits and claims in the ordinary course of business. The Company does not
believe that the disposition of any such other suits or claims will have a
material adverse effect on the continuing operations or financial position of
the Company.
Item 4. Submission of Matters To Vote of Security Holders.
Not applicable.
PART II
Item 5. Market for Registrant's Common Equity and Related Shareholder Matters.
The Company's common stock has been traded on the American Stock Exchange under
the symbol "PMD" since April 27, 1995. Prior to such date, the stock was traded
on the NASDAQ Small-Cap Market under the symbol "PCMC". The following table sets
forth for the periods indicated the range of prices for the Company's common
stock as reported by the National Quotation Bureau, Inc. (through April 26,
1995) and as reported by the American Stock Exchange thereafter. As of March 14,
1997, there were 526 recordholders of the Company's common stock.
Calendar Period High Low
- --------------- -------- ------
1996
- ----
First Quarter 6 1/2 5 1/8
Second Quarter 8 6 1/16
Third Quarter 7 11/16 6
Fourth Quarter 6 3/4 5 3/4
1995
- ----
First Quarter 3 7/16 2 1/2
Second Quarter 3 3/8 2 5/8
Third Quarter 9 3 3/8
Fourth Quarter 6 4 3/4
11
<PAGE> 12
On July 3, 1996, the Company distributed a 3% stock dividend to shareholders of
record on June 21, 1996. The share price information set forth above has not
been adjusted to reflect the stock dividend. On December 19, 1996, the Company
declared a cash dividend of $0.02 a share payable on January 30, 1997 to holders
of record at the close of business on January 15, 1997. Subsequently, on March
4, 1997, the Company declared a cash dividend of $0.02 per share payable on
April 9, 1997 to shareholders of record at the close of business on March 20,
1997. Future dividends may be made at the discretion of the Board of Directors.
Item 6. Selected Financial Data
The following Selected Financial Data for the years ended December 31, 1996,
1995 and 1994 have been derived from the financial statements of the
Company as audited by Arthur Andersen LLP, the Company's independent public
accountants. This Selected Financial Data should be read in conjunction with,
and is qualified in its entirety by reference to, the financial statements and
related notes thereto included elsewhere in this Report. The Selected Financial
Data for the years ended December 31, 1993 and 1992 were also derived from the
audited financial statements of the Company, although reference to these
financial statements and related notes thereto is not included in this report.
<TABLE>
<CAPTION>
As of and for the Periods Ended
----------------------------------------------------
(In thousands except per share data)
December 31,
----------------------------------------------------
1996 1995 1994 1993 1992
-------- -------- -------- -------- --------
<S> <C> <C> <C> <C> <C>
Revenue ............................ $ 12,214 $ 10,111 $ 8,734 $ 6,576 $ 3,974
Gross profit ....................... 7,233 5,422 5,037 3,886 2,121
Income from operations ............. 2,409 1,301 1,742 986 (568)
Net income ......................... 2,492 1,559 1,831 953 (521)
Net income per common
and common equivalent
share ................. .11 .07 09 .05 (.03)
Weighted average common
and common equivalent
shares outstanding ............... 22,164 23,404 20,023 20,522 15,461
Total Assets ....................... 15,745 10,217 10,289 4,385 3,025
Working Capital .................... 11,402 6,788 7,658 1,935 1,373
Shareholder's Equity ............... $ 9,484 $ 9,580 $ 3,536 $ 2,560 $ 2,560
</TABLE>
Item 7. Management's Discussions and Analysis of Financial Condition
and Results of Operations.
12
<PAGE> 13
REVENUE
The year ended December 31, 1996 was another record year for revenue. Revenue
was $12,214,198 in 1996 as compared to $10,110,934 in 1995 and $8,734,156 in
1994, representing an increase of 21% in 1996 and 16% in 1995. These increases
were due primarily to the addition of new clients and expanded volume from
existing clients in targeted industries such as manufacturing, service, retail,
mining, and law enforcement. Revenue included $1,886,000 $1,822,000 and
$2,059,000 from Blockbuster in 1996, 1995 and 1994, respectively. There can be
no assurance that Blockbuster's testing volume and the Company's resulting
revenue derived from Blockbuster will reach the same levels in 1997 as in 1996.
DIRECT COSTS AND EXPENSES
The following table sets forth the direct costs of revenue as a percentage of
revenue and general and administrative expenses, marketing and selling expenses
and research and development expenses as a percentage of revenue for the years
ended December 31:
1996 1995 1994
---- ---- ----
Direct costs 41% 46% 42%
General and administrative expenses 19% 19% 15%
Marketing and selling expenses 17% 17% 18%
Research and development expenses 3% 4% 5%
Direct Costs
Direct costs for the year ended December 31, 1996 were $4,981,221 as compared to
$4,689,227 in 1995 and $3,696,944 in 1994. The increases of $291,994 and
$992,283 in 1996 and 1995, respectively, are due primarily to increases in the
volume of samples tested in each such period. The decrease in direct costs as a
percentage of revenue in 1996 as compared to 1995 is primarily the result of
increased efficiencies resulting from increased sales volume.
General and Administrative Expenses
General and Administrative Expenses were $2,362,074, $1,946,648 and $1,342,653
for the years ended December 31, 1996, 1995 and 1994, respectively. The $415,426
increase in 1996 was due primarily to the higher costs incurred by the Company
as a result of its continued revenue growth, principally salaries, legal,
regulatory and bad debt expenses. The $603,995 increase in 1995 was also due
primarily to the higher costs incurred by the Company as a result of its revenue
growth.
Marketing and Selling Expenses
Marketing and Selling Expenses for the year ended December 31, 1996 were
$2,048,477 as compared to $1,737,543 in 1995 and $1,546,084 in 1994. The
increase in 1996 of $310,934 was due primarily to increased marketing expenses
related to an expanded sales staff and increased marketing activities. The
$191,459 increase in 1995 as compared to 1994 was due primarily to increased
marketing expenses.
13
<PAGE> 14
Research and Development Expenses
Research and Development Expenses remained virtually unchanged at $413,693 in
1996 as compared to $436,385 in 1995 and $406,345 in 1994. As a percentage of
revenues, Research & Development Expenses decreased due to increases in revenues
in the periods.
OTHER INCOME (EXPENSE)
Interest income in 1996, 1995 and 1994 resulted primarily from temporary
investments of cash derived from operations, and from the exercise of stock
options and warrants. The decrease in interest expense in 1996 and 1995 results
from the repayment of capital lease obligations attributable to the financing of
certain equipment purchases in 1993 through capital lease arrangements.
NET INCOME
Net income for December 31, 1996, 1995 and 1994 was $2,491,981, $1,558,686 and
$1,831,230 respectively. The increase in 1996 was primarily due to increased
revenues, and related efficiencies in direct costs derived from increased sales
volume. The decrease in 1995 was primarily due to increases in direct costs and
increased general and administrative expenses which exceeded increases in
revenues in such year. The provision for income taxes in 1996 and 1995
represents the alternative minimum tax due, and provision for state corporate
income taxes as required by the Internal Revenue Code. The Company had total net
operating loss carryforwards at December 31, 1996 of approximately $3,586,000
available to offset future federal taxable income.
LIQUIDITY AND CAPITAL RESOURCES
The Company's cash and investment balances at December 31, 1996 amounted to
$9,833,405. Cash generated from operations in 1996 was $2,352,557. The Company
also received $2,756,667 of net proceeds from the exercise of warrants and stock
options in 1996.
Working capital at December 31, 1996 amounted to $11,402,723 as compared to
$6,788,513 at December 31, 1995. The increase of $4,614,210 during 1996 resulted
primarily from increased sales and the exercise of stock options and warrants
during the year.
Management believes that cash on hand, coupled with future operating profits and
the proceeds from the exercise of outstanding options, should be adequate to
fund anticipated working capital requirements. Depending upon the Company's
results of operations, its future capital needs and available marketing
opportunities, the Company may use various financing sources to raise additional
equity capital. Such sources could include joint ventures or additional private
equity placements.
The Company's capital expenditures were $736,432 in 1996, $1,269,118 in 1995 and
$528,819 in 1994. The expenditures in 1996 were primarily a result of expansion
of the Company's laboratory facilities. Capital expenditures for 1997 are
expected to be approximately $600,000 and are expected to be funded through cash
generated from operations and from existing cash reserves.
14
<PAGE> 15
In December 1994, the Company's Board of Directors authorized the repurchase of
up to 1 million shares of the Company's common stock. During 1995, the Company
purchased a total of 699,387 shares of Common Stock for $2,676,793. This program
is a direct result of the Company's solid financial condition and
cash-generating capability, and it was authorized after evaluating various
alternatives to enhance long-term share owner value.
On July 3, 1996, the Company distributed a 3% stock dividend to shareholders of
record on June 21, 1996. The shares issued in the stock dividend represented
shares which the Company acquired in the stock repurchase program. This
transaction resulted in an increase of $4,667,516 in the accumulated deficit
(633,006 shares distributed at a fair market value of $7.375 per share on June
31, 1996, the record date). Treasury stock was reduced by $2,422,730 as a result
of this distribution. Average shares outstanding and all per share amounts
included in the accompanying financial statements and Notes are based on the
increased number of shares giving retroactive effect to the stock dividend.
On December 19, 1996, the Company declared a cash dividend of $0.02 a share
payable on January 30, 1997 to holders of record at the close of business on
January 15, 1997. This cash dividend resulted in an increase of $437,221 in the
accumulated deficit and accrued dividends payable at December 31, 1996
On March 4, 1997, the Company declared a cash dividend of $0.02 per share
payable on April 9, 1997 to shareholders of record at the close of business on
March 20, 1997.
Item 8. Financial Statements and Supplementary Data
The financial statements and financial statement schedules are incorporated by
reference in this report on pages F-1 through F-12.
Item 9. Changes in and Disagreements with Accountants on Accounting and
Financial Disclosure.
None.
15
<PAGE> 16
PART III
Item 10. Directors and Executive Officers of the Registrant.
Following is a list that sets forth as of March 31, 1997 the names, ages and
positions within the Company of all of the Executive Officers of the Company and
the Directors of the Company. Each such director has been nominated for
reelection at the Company's 1997 Annual Meeting, to be held on May 8, 1997.
NAME AGE POSITION
- ---- --- --------
Raymond C. Kubacki, Jr. 52 Chief Executive
Officer, President,
Director
Werner A. Baumgartner, Ph.D. 61 Chairman of the
Board, Director
A. Clinton Allen 53 Vice Chairman of
the Board, Director
Bruce M. Stillwell 35 Vice President,
Treasurer, Controller
Donald J. Kippenberger, Ph.D. 50 Vice President-
Laboratory Operations
Thomas Cairns, Ph.D., D.Sc. 56 Vice President-
Technology Research
& Development
William Thistle, Esq. 47 Vice President,
General Counsel
Donald F. Flynn 57 Director
John J. Melk 60 Director
Fred J. Weinert 49 Director
All Directors hold office until the next annual meeting of stockholders or until
their successors are elected. Officers serve at the discretion of the Board of
Directors.
Mr. Kubacki joined the Company in July 1991 as Director and as President and
Chief Executive Officer. During the five years prior to joining the Company, he
served as Vice President-National Accounts and Director of Sales and Marketing
for Reliance COMM/TEC Corporation, a subsidiary of Reliance Electric Co.
Dr. Baumgartner, a founder of the Company, has served as Chairman of the Board
and a Director of the Company since its organization in September 1986. Dr.
Baumgartner has served as the Company's Director of Scientific and Regulatory
16
<PAGE> 17
Affairs since May 1989. Dr. Baumgartner received his Ph.D. in physical chemistry
in 1963 from the University of New South Wales, Sydney, Australia, and has been
engaged in physical and biophysical chemistry research since 1960, holding
research and teaching positions at University of New South Wales; Long Beach
State University; Jet Propulsion Laboratory at California Institute of
Technology; University of California, Los Angeles; and University of Southern
California. Dr. Baumgartner has been the director of the Radioimmunoassay and In
Vitro Laboratory of the Nuclear Medicine Service, Veterans Administration
Hospital, Wadsworth, Los Angeles, California, since 1976, serving in such
capacity on a part-time basis since February 1987.
Mr. Allen is Chairman and Chief Executive Officer of A.C. Allen & Company, Inc.,
an investment banking consulting firm located in Cambridge, Massachusetts. Mr.
Allen currently serves as a director of Swiss Army Brands, Inc. and is a member
of its Executive Committee; and as a director of SweetWater, Inc. He also serves
as a director and Vice Chairman of The DeWolfe Companies, Inc. Mr. Allen has
been a director of the Company since 1989.
Dr. Kippenberger joined the Company in January 1994 as Vice President of
Laboratory Operations. From 1987 to 1990, he was the Technical Director of the
Wiesbaden Forensic Toxicology Drug Testing Laboratory, one of the U.S. Army's
largest drug testing laboratories. From 1990 to 1993 he served as the Forensic
Toxicology Consultant to the U.S. Army Surgeon General, where he directed
policy, technical operations and inspection oversight of the four U.S. Army
toxicology drug testing laboratories. Dr. Kippenberger is a National Institute
on Drug Abuse (NIDA) inspector, and a College of American Pathologists
inspector.
Dr. Cairns joined the Company in July 1995 as Vice President of Technology
Research & Development. An authority in the field of mass spectrometry, Dr.
Cairns served as a Senior Research Scientist with the Food and Drug
Administration during his 21-year tenure with that agency. He also served on the
FDA Senior Science Counsel from 1991 to 1995 and served as Chairman of the FDA
Science Forum from 1992 to 1995. In addition, Dr. Cairns holds an academic
appointment with the University of Southern California as Adjunct Professor of
Pharmaceutical Science, School of Pharmacy, and was recently appointed Science
Advisor to the FDA.
Mr. Thistle joined the Company in September 1995 as Vice President and General
Counsel. Prior to joining the Company, he served as Associate General Counsel
for MGM Grand in Las Vegas from 1993 to 1995. From 1989 to 1993, Mr. Thistle was
Associate General Counsel for Harrah's Casino Resorts.
Mr. Stillwell joined the Company in September 1995 as Vice President,
Controller. In January 1996, he was elected Treasurer. Prior to joining the
Company, he served in various positions including Controller for Organogenesis
Inc. from 1988 to 1995. From 1983 to 1988, Mr. Stillwell was an auditor for
Arthur Andersen LLP.
Mr. Flynn has been the sole stockholder and Chairman of the Board of Flynn
Enterprises, Inc., a financial advisory and venture capital firm, since February
1988. Mr. Flynn also was Chairman of the Board from July 1992 until February
1996 and Chief Executive Officer from July 1992 until May 1995 of Discovery
Zone, Inc., an operator of indoor entertainment and fitness facilities for
children. On March 25,
17
<PAGE> 18
1996, Discovery Zone, Inc. filed a voluntary petition under Chapter 11 of the
U.S. Bankruptcy Code. From 1972 to December 1990, Mr. Flynn served in various
positions with WMX Technologies, Inc. (formerly Waste Management, Inc.)
including Senior Vice President and Chief Financial Officer. Mr. Flynn currently
serves as a director of WMX Technologies, Inc. and its affiliated entities,
Waste Management International plc and Wheelabrator Technologies, Inc. Mr. Flynn
also serves as a director of Extended Stay America, Inc.; an owner and operator
of Extended-Stay lodging facilities. Mr. Flynn has been a director of the
Company since 1989.
Mr. Melk currently serves as Chairman of H20 Plus, L.P., which develops and
manufactures health and beauty products and distributes them through a
company-owned chain of specialty retail stores, as well as over 300
wholesale/department stores. He also serves as Chairman of MW Partners, an
investor in commercial and residential real estate investments. From 1987 to
1989, Mr. Melk was Vice Chairman of the Board of Blockbuster Entertainment
Corporation. From 1971 to 1975, Mr. Melk was Vice President of Corporate
Development for WMX Technologies and from 1975 to 1984 held the position of
President of W.M.I. International, Ltd. based in London, England. He is a
director of Republic Industries, Inc., and Extended Stay America, Inc. Mr. Melk
has been a director of the Company since 1991.
Mr. Weinert serves as President of San Telmo, Inc. (investment group),
Barrington Services Group (a business advisory firm and commercial real estate
developer), Here's Hollywood, Inc. (a Blockbuster Video franchisee) and Vice
President of H20 Plus, S.A. (a distributor of cosmetics, bath products and
fragrances in Argentina, Chile and Uruguay). From June 1989 to February 1995 he
was President of H20 Plus L.P., MW Partners, and Century Entertainment Ltd.
Previous to that he was President of Waste Management International, Inc. from
December 1983 to June 1989. For over 10 years he has served on the Business
Advisory Council for the University of Dayton. Mr. Weinert has been a director
of the Company since 1991.
Item 11. Executive Compensation.
The information required by this item will be set forth in the Proxy Statement
of the Company relating to the 1997 Annual Meeting of Stockholders to be held on
May 8, 1997 and is incorporated herein by reference.
Item 12. Security Ownership of Certain Beneficial Owners and Management.
The information required by this item will be set forth in the Proxy Statement
of the Company relating to the 1997 Annual Meeting of Stockholders to be held on
May 8,1997 and is incorporated herein by reference.
Item 13. Certain Relationships and Related Transactions.
The information required by this item will be set forth in the Proxy Statement
of the Company relating to the 1997 Annual Meeting of Stockholders to be held on
May 8, 1997 and is incorporated herein by reference.
18
<PAGE> 19
PART IV
Item 14. Exhibits, Financial Statement Schedules, and Reports on Form 8-K.
(a) (1) Financial Statements: Page
----
Report of Independent Public Accountants F-1
Balance Sheets as of December 31, 1996 and 1995 F-2
Statements of Income for the Years
Ended December 31, 1996, 1995 and 1994 F-3
Statements of Shareholders' Equity for the Years
Ended December 31, 1996, 1995 and 1994 F-4
Statements of Cash Flows for the Years
Ended December 31, 1996, 1995 and 1994 F-5
Notes to Financial Statements F-6
(2) Financial Statements Schedules
(3) Exhibits - (See the Index to Exhibits included
elsewhere in this report)
(b) Reports on Form 8-K
None
19
<PAGE> 20
PSYCHEMEDICS CORPORATION
10-K
Index to Exhibits
Exhibit Page or
Number Description Reference
- ------ ----------- ---------
3 Articles of Incorporation and By-Laws
3.1 Certificate of Incorporation filed
September 24, 1986 - (Incorporated by reference from
the Registrant's Registration Statement on Form S-18,
File No. 33-10186 LA).
3.2 Amendment to Certificate of Incorporation filed
October 29, 1986 - (Incorporated by reference from
the Registrant's Registration Statement on Form S-18,
File No. 33-10186 LA).
3.3 Amendment to Certificate of Incorporation filed
July 12, 1989 - (Incorporated by reference from
the Registrant's Annual Report on Form 10-K
for the fiscal year ended June 30, 1989.)
3.4 Amendment to Certificate of Incorporation filed
August 7, 1990 - (Incorporated by reference from the
Registrant's Quarterly Report on Form 10-Q for the
Quarter ended September 30, 1990 as amended by
a First Amendment on Form 8 filed December 15, 1990.)
3.5 Amendment to Certificate of Incorporation filed
May 9, 1991 - (Incorporated by reference from the
Registrant's Quarterly Report on Form 10-Q for the
quarter ended June 30, 1991.)
3.6 By-Laws of the Company - (Incorporated by reference
from the Registrant's Registration Statement on Form S-18,
File No. 33-10186 LA).
4 Instruments Defining the Rights of Security Holders
4.1 Specimen Stock Certificate - (Incorporated by reference
from the Registrant's Registration Statement on Form S-18,
File No. 33-10186 LA).
10 Material Contracts
<PAGE> 21
10.1 License Agreement with Werner Page or
Baumgartner, Ph.D. and Annette Baumgartner Reference
dated January 17, 1987 - (Incorporated by reference ---------
from the Registrant's Registration Statement on Form
S-18, File No. 33-10186 LA).
10.2 License Agreement with Home Office
Reference Laboratory dated November 17, 1988 -
(Incorporated by reference from the Registrant's
Quarterly Report on Form 10-Q for the quarter ended
December 31, 1988.)
10.3 License Agreement with Lifecodes
Corporation dated February 24, 1989 -
(Incorporated by reference from the Registrant's
Quarterly Report on Form 10-Q for the quarter ended
March 31, 1989.)
10.4 Employment Agreement with Werner A.
Baumgartner, Ph.D. dated May 15, 1994
(Incorporated by reference from the Registrant's
Quarterly Report on Form 10-Q for the quarter ended
June 30, 1995.)
10.5 Securities Purchase Agreement re: sale
of 3,500,000 shares of Common Stock
and 4,200,000 Common Stock Purchase
Warrants dated May 15, 1989 - (Incorporated
by reference from the Registrant's Current Report on
Form 8-K filed May 30, 1989.)
10.6 Amendment dated as of June 30, 1990 to Securities
Purchase Agreement dated May 15, 1989 -
(Incorporated by reference from the Registrant's
Annual Report on Form 10-K for the fiscal year
ended December 31, 1991.)
10.7* 1989 Employee Stock Option Plan,
as amended - (Incorporated by reference from the
Registrant's 1997 Annual Proxy Statement.)
10.8* 1989 Non-Qualified Stock Option Plan,
as amended Filed herewith
10.9* 1991 Non-Qualified Stock Option Plan -
(Incorporated by reference from the Registrant's
Annual Report on Form 10-K for the fiscal year
ended December 31, 1991.)
10.10* Employment Agreement with Raymond C.
Kubacki, Jr. effective July 16, 1991 (Incorporated
by reference from the Registrant's Annual Report
on From 10-K for the fiscal year ended December 31, 1991.)
<PAGE> 22
10.11 Lease dated October 6, 1992 with Mitchell H. Page or
Hersch, et. al with respect to premises in Reference
Culver City, California - (Incorporated by reference ---------
from the Registrant's Annual Report on Form 10-KSB
for the fiscal year ended December 31, 1992.)
10.12 Security Agreement dated October 6, 1992
with Mitchell H. Hersch et. al - (Incorporated by
reference from the Registrant's Annual Report on
Form 10-KSB for the fiscal year ended December 31, 1992.)
10.13 Lease Agreement dated December 30, 1992
with General Electric Capital Corporation -
(Incorporated by reference from the Registrant's
Annual Report on Form 10-KSB for the fiscal year ended
December 31, 1992.)
10.14 Letter of Credit Agreement dated December 29,
1992 with General Electric Capital Corporation -
(Incorporated by reference from the Registrant's Annual
Report on Form 10-KSB for the fiscal year ended
December 31, 1992.)
10.15 Standby Letter of Credit dated December 29,
1992 with Brown Brothers Harriman & Co. -
(Incorporated by reference from the Registrant's Annual
Report on Form 10-KSB for the fiscal year ended
December 31, 1992.)
10.16* Employment Agreement with Donald J.
Kippenberger, Ph.D. dated January 1, 1994 -
(Incorporated by reference from the Registrant's
Quarterly Report on Form 10-Q for the quarter ended
June 30, 1995.)
10.17* Employment Agreement with Thomas Cairns Ph.D.,
D.Sc. dated July 1, 1995 - (Incorporated by reference
from the Registrant's Quarterly Report on Form 10-Q for
the quarter ended June 30, 1995.)
11 Statement re: Computation of Per Share Earnings Filed herewith
23 Consents of Experts and Counsel
23.1 Consent of Arthur Andersen LLP Filed herewith
- ----------
* Represents a management contract or compensatory plan in which a director
or named executive office of the Registrant participates.
<PAGE> 23
SIGNATURES
Pursuant to the requirements of Sections 13 or 15 (d) of the Securities Exchange
Act of 1934, the registrant has duly caused this Report to be signed on its
behalf by the undersigned, thereunto duly authorized.
PSYCHEMEDICS CORPORATION
By: /s/ Raymond C. Kubacki, Jr.
-----------------------------------
Raymond C. Kubacki, Jr.
President and Chief Executive Officer
Date: March 28, 1997
Pursuant to the requirements of the Securities Exchange Act of 1934, this Report
has been signed below by the following persons on behalf of the Registrant and
in the capacities and on the dates indicated.
/s/ Raymond C. Kubacki, Jr. March 28, 1997
- ----------------------------------------
Raymond C. Kubacki, Jr.
President and Chief Executive
Officer, Director
(Principal Executive Officer)
/s/ Bruce M. Stillwell March 28, 1997
- ----------------------------------------
Vice President, Treasurer, & Controller
(Principal Financial Officer)
/s/ Werner A. Baumgartner, Ph.D. March 28, 1997
- ---------------------------------------
Werner A. Baumgartner, Ph.D.
Director
/s/ A. Clinton Allen March 28, 1997
- ----------------------------------------
A. Clinton Allen
Director
/s/ Donald F. Flynn March 28, 1997
- ----------------------------------------
Donald F. Flynn
Director
/s/ John J. Melk March 28, 1997
- ----------------------------------------
John J. Melk
Director
/s/ Fred J. Weinert March 28, 1997
- ----------------------------------------
Fred J. Weinert
Director
20
<PAGE> 24
REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS
To Psychemedics Corporation:
We have audited the accompanying balance sheets of PSYCHEMEDICS CORPORATION (a
Delaware corporation) as of December 31, 1996 and 1995, and the related
statements of income, shareholders' equity and cash flows for each of the three
years in the period ended December 31, 1996. These financial statements are the
responsibility of the Company's management. Our responsibility is to express an
opinion on these financial statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Psychemedics Corporation as of
December 31, 1996 and 1995, and the results of its operations and its cash flows
for each of the three years in the period ended December 31, 1996, in conformity
with generally accepted accounting principles.
ARTHUR ANDERSEN LLP
Boston, Massachusetts
February 25, 1997 (except with respect
to the matter discussed in Note 8, as
to which the date is March 4, 1997)
F-1
<PAGE> 25
PSYCHEMEDICS CORPORATION
BALANCE SHEETS
December 31,
------------------------------
1996 1995
------------ -------------
ASSETS
CURRENT ASSETS:
Cash and cash equivalents $ 1,462,678 $ 193,787
Short-term investments 8,370,727 5,279,596
Receivables 2,657,416 1,722,770
Laboratory supplies 230,777 253,216
Prepaid expenses and
other current assets 129,828 72,247
------------ ------------
Total current assets 12,851,426 7,521,616
------------ ------------
EQUIPMENT AND LEASEHOLD IMPROVEMENTS:
Capitalized software 602,521 296,460
Office furniture and equipment 782,511 585,411
Laboratory equipment
and leasehold improvements 3,458,380 3,225,109
------------ ------------
4,843,412 4,106,980
Less: Accumulated depreciation
and amortization 2,399,919 1,864,398
------------ ------------
2,443,493 2,242,582
------------ ------------
OTHER ASSETS - NET 449,601 453,295
------------ ------------
$ 15,744,520 $ 10,217,493
============ ============
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Current portion of obligations
under capital leases $ -- $ 16,459
Accounts payable 395,434 466,412
Accrued dividend payable 437,217 --
Accrued expenses 332,244 194,665
Accrued income taxes 283,808 55,567
------------ ------------
Total current liabilities 1,448,703 733,103
------------ ------------
COMMITMENTS (Note 5)
SHAREHOLDERS' EQUITY:
Preferred stock, $.005 par value;
authorized 1,000,000
shares; none outstanding -- --
Common stock, $.005 par value;
authorized 50,000,000
shares; issued 21,758,087
and 20,288,280 shares
in 1996 and 1995, respectively 108,790 101,441
Paid-in capital 20,722,137 15,728,033
Accumulated deficit (6,281,047) (3,668,291)
Treasury stock, at cost;
66,381 shares in 1996
and 699,387 shares in 1995 (254,063) (2,676,793)
------------ ------------
Total shareholders' equity 14,295,817 9,484,390
------------ ------------
$ 15,744,520 $ 10,217,493
============ ============
The accompanying notes are an integral part of these financial statements.
F-2
<PAGE> 26
PSYCHEMEDICS CORPORATION
STATEMENTS OF INCOME
Years Ended December 31,
------------------------------------------
1996 1995 1994
----------- ----------- -------------
REVENUE $12,214,198 $10,110,934 $ 8,734,156
DIRECT COSTS 4,981,221 4,689,227 3,696,944
----------- ----------- ------------
Gross profit 7,232,977 5,421,707 5,037,212
----------- ----------- ------------
EXPENSES:
General and administrative 2,362,074 1,946,648 1,342,653
Marketing and selling 2,048,477 1,737,543 1,546,084
Research and development 413,693 436,385 406,345
----------- ----------- ------------
4,824,244 4,120,576 3,295,082
----------- ----------- ------------
Income from operations 2,408,733 1,301,131 1,742,130
----------- ----------- ------------
INTEREST INCOME, net 360,248 344,755 155,200
----------- ----------- ------------
INCOME BEFORE PROVISION
FOR INCOME TAXES 2,768,981 1,645,886 1,897,330
PROVISION FOR INCOME TAXES 277,000 87,200 66,100
----------- ----------- ------------
NET INCOME $ 2,491,981 $ 1,558,686 $ 1,831,230
=========== =========== ============
NET INCOME PER COMMON
AND COMMON EQUIVALENT SHARE $ 0.11 $ 0.07 $ 0.09
=========== =========== ============
WEIGHTED AVERAGE COMMON AND
COMMON EQUIVALENT SHARES OUTSTANDING 22,164,226 23,404,058 19,921,614
=========== =========== ============
The accompanying notes are an integral part of these financial statements.
F-3
<PAGE> 27
PSYCHEMEDICS CORPORATION
STATEMENTS OF SHAREHOLDERS' EQUITY
<TABLE>
<CAPTION>
Common Stock Treasury Stock
--------------------- -------------------
$0.005 Paid-In Accumulated
Shares Par Value Capital Deficit Shares Amount Total
------ --------- ------- ------- ------ ------ -----
<S> <C> <C> <C> <C> <C> <C> <C>
BALANCE, December 31, 1993 15,044,829 $ 75,224 $ 10,518,768 $(7,058,207) - $ - $ 3,535,785
Sale of common stock through the
exercise of warrants, net of
related costs 4,216,800 21,084 3,725,555 - - - 3,746,639
Sale of common stock through the -
stock option plans 249,250 1,246 465,309 - - - 466,555
Net income - - - 1,831,230 - - 1,831,230
---------- ---------- ------------- ----------- ------- ----------- -----------
BALANCE, December 31, 1994 19,510,879 $ 97,554 $ 14,709,632 $(5,226,977) - - $ 9,580,209
Sale of common stock through the
exercise of warrants, net of
related costs 498,951 2,495 504,583 - - - 507,078
Sale of common stock through the
stock option plans 278,450 1,392 513,818 - - - 515,210
Purchases of treasury stock - - - - 699,387 (2,676,793) (2,676,793)
Net income - - - 1,558,686 - - 1,558,686
---------- ---------- ------------- ----------- ------- ----------- -----------
BALANCE, December 31, 1995 20,288,280 $ 101,441 $ 15,728,033 $(3,668,291) 699,387 $(2,676,793) $ 9,484,390
Sale of common stock through the
exercise of warrants, net of
related costs 987,787 4,939 1,970,635 - - - 1,975,574
Sale of common stock through the
stock option plans 482,020 2,410 778,683 - - - 781,093
Distribution of 3% stock dividend - - 2,244,786 (4,667,516) (633,006) 2,422,730 -
Cash dividend payable - - - (437,221) - - (437,221)
Net income - - - 2,491,981 - - 2,491,981
---------- ---------- ------------- ----------- ------- ----------- -----------
BALANCE, December 31, 1996 21,758,087 $ 108,790 $ 20,722,137 $(6,281,047) 66,381 $ (254,063) $14,295,817
========== ========== ============= =========== ======= =========== ===========
</TABLE>
The accompanying notes are an integral part of these financial statements.
F-4
<PAGE> 28
PSYCHEMEDICS CORPORATION
STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>
Years Ended December 31,
-----------------------------------------
1996 1995 1994
---------- ---------- -----------
<S> <C> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income $ 2,491,981 $ 1,558,686 $ 1,831,230
Adjustments to reconcile net income to net
cash provided by operating activities:
Depreciation and amortization 535,522 599,714 418,800
Changes in current assets and liabilities:
Receivables (934,646) (305,069) (20,049)
Laboratory supplies 22,439 (64,513) (57,373)
Prepaid expenses and other current assets (57,581) 7,440 (4,720)
Accounts payable (70,978) 162,850 (15,673)
Accrued expenses 137,579 22,971 (41,469)
Accrued income taxes 228,241 (8,717) 56,784
----------- ----------- -----------
Net cash provided by operating activities 2,352,557 1,973,362 2,167,530
----------- ----------- -----------
CASH FLOWS FROM INVESTING ACTIVITIES:
Sales (purchases) of short-term investments - net (3,091,131) 840,857 (6,120,453)
Purchases of equipment and leasehold improvements (736,432) (1,269,118) (528,819)
(Increase) decrease in other assets 3,689 (88,071) (48,837)
----------- ----------- -----------
Net cash used in investing activities (3,823,874) (516,332) (6,698,109)
----------- ----------- -----------
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments on obligations under capital leases (16,459) (153,514) (139,778)
Net proceeds from the sale of common stock 2,756,667 1,022,288 4,213,194
Purchases of treasury stock -- (2,676,793) --
----------- ----------- -----------
Net cash provided by (used in) financing activities 2,740,208 (1,808,019) 4,073,416
----------- ----------- -----------
NET INCREASE (DECREASE) IN CASH AND CASH
EQUIVALENTS 1,268,891 (350,989) (457,163)
CASH AND CASH EQUIVALENTS, beginning of year 193,787 544,776 1,001,939
----------- ----------- -----------
CASH AND CASH EQUIVALENTS, end of year $ 1,462,678 $ 193,787 $ 544,776
=========== =========== ===========
</TABLE>
Supplemental Cash Flow Information
Cash paid for interest during the years ended December 31, 1996, 1995 and 1994
was $578, $9,178 and $23,630, respectively. Cash paid for income taxes during
the years ended December 31, 1996, 1995 and 1994 was $119,000, $67,490 and
$16,411, respectively. At December 19, 1996, a $0.02 per share dividend was
declared to shareholders of record on January 15, 1997. An accrued dividend
payable in the amount of $437,217 has been reflected in the financial statements
for this transaction.
The accompanying notes are an integral part of these financial statements.
F-5
<PAGE> 29
PSYCHEMEDICS CORPORATION
NOTES TO FINANCIAL STATEMENTS
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The Company
Psychemedics Corporation (the Company) was incorporated in 1986. The Company
utilizes a patented hair analysis method involving radioimmunoassay technology
to analyze human hair to detect abused substances. The founder of the Company
has granted to the Company an exclusive license to all his rights in this hair
analysis technology, including his rights to the drug extraction method (see
Note 2).
Cash and Cash Equivalents and Short-Term Investments
The Company considers all highly liquid investments with maturities of three
months or less at the time of acquisition to be cash equivalents, which consist
of money market accounts at December 31, 1996. Short-term investments have
maturities of greater than three months and less than one year and consist of
securities issued by the U.S. Government at December 31, 1996 and 1995.
The Company adopted Statement of Financial Accounting Standards (SFAS) No. 115,
Accounting for Certain Investments in Debt and Equity Securities , effective
January 1, 1994. Under SFAS No. 115, investments that the Company has the
positive intent and ability to hold to maturity are reported at amortized cost,
which approximates fair market value, and are classified as held-to-maturity.
These amounts include all short-term investments.
Equipment and Leasehold Improvements
Equipment and leasehold improvements are stated at cost. Depreciation and
amortization are provided over the estimated useful lives of the assets, using
the straight-line method. The estimated useful lives of the assets are as
follows:
Capitalized software 5 years
Office furniture and equipment 5 to 7 years
Laboratory equipment 5 to 7 years
Leasehold improvements 5 years or life of lease
Other Assets
Included in other assets are patent application costs of approximately $450,000
and $504,000 as of December 31, 1996 and 1995, respectively, which relate to the
drug extraction method. The Company is amortizing the cost of these patents over
10 years from the date of grant. The Company recorded amortization of $60,000
and $36,000 during 1996 and 1995, respectively. The Company evaluates the
realizability of its patents based on estimated cash flows to be generated from
such assets as compared to the original estimates used in measuring the assets.
To the extent impairment is identified, the Company will recognize a write-down
of the related assets. To date, no impairment has been identified.
F-6
<PAGE> 30
Revenue Recognition
Revenues are recognized upon reporting drug test results to the customer.
Research and Development Expenses
The Company charges research and development expenses to operations as incurred.
Significant Customers
One customer had amounts due to the Company of approximately $457,000 and
$330,000 at December 31, 1996 and 1995, respectively. This customer accounted
for 15%, 18% and 24% of revenues during 1996, 1995 and 1994, respectively.
Management Estimates
The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements and
the reported amounts of revenues and expenses during the reporting period.
Actual results could differ from those estimates.
Net Income per Common and Common Equivalent Share
Net income per common and common equivalent share for 1996, 1995, and 1994 is
based on the weighted average number of common and common equivalent shares
outstanding as computed using the treasury-stock method. Fully dilutive net
income per share has not been presented as the difference from primary net
income per share is not significant.
Reclassifications
Certain amounts in the prior years financial statements have been reclassified
to conform to current year presentation.
New Accounting Standard
In February 1997, the Financial Accounting Standards Board issued SFAS No. 128
Earnings Per Share. SFAS No. 128 establishes standards for computing and
presenting earnings per share and applies to entities with publicly held common
stock or potential common stock. This statement is effective for fiscal years
ending after December 15, 1997 and early adoption is not permitted. When
adopted, the statement will require restatement of prior years' earnings per
share. The Company will adopt this statement for its fiscal year ended December
31, 1997.
Pro forma calculations of basic and diluted earnings per share as required by
SFAS No. 128 are as follows:
F-7
<PAGE> 31
1996 1995 1994
---- ---- ----
Basic EPS
Net income available to
common shareholders $ 2,491,981 $1,558,686 $1,831,230
Weighted average common
shares outstanding net of
treasury shares 21,145,699 21,304,967 18,441,390
----------- ---------- ----------
Basic EPS $ 0.12 $ 0.07 $ 0.10
=========== ========= ==========
Diluted EPS
Net income available to common
shareholders $ 2,491,981 $1,558,686 $1,831,230
Weighted average common
and common equivalent
shares outstanding 22,164,226 23,404,058 19,921,614
---------- ---------- ----------
Diluted EPS $ 0.11 $ 0.07 $ 0.09
=========== =========== ==========
2. LICENSE AGREEMENTS
The Company has a royalty-free license from the founder for the proprietary
rights to the patented hair analysis technology used by the Company in its drug
testing services. The Company has two agreements to sublicense its technology,
which have not generated significant royalties to date.
3. INCOME TAXES
The Company accounts for income taxes under SFAS No. 109, Accounting for Income
Taxes.
The Company has total net operating loss carryforwards at December 31, 1996 of
approximately $3,586,000 available to offset future federal taxable income, if
any. Approximately $785,000 of these loss carryforwards expire in 2005,
$2,223,000 in 2006, and $578,000 in 2007. The net operating loss carryforward is
comprised of approximately $938,000 of losses from operations, and approximately
$2,648,000 from the exercise of certain options and warrants which will increase
paid-in capital when previously unrealized stock option benefits are recognized.
These net operating loss carryforwards are subject to review and possible
adjustment by the Internal Revenue Service. In addition, existing tax
regulations contain provisions that may limit the net operating loss
carryforward that the Company may utilize in any given year in the event of
certain significant changes in ownership interest.
The provision for income taxes in the accompanying 1996, 1995 and 1994
statements of income represents the alternative minimum tax due and provision
for state corporate income taxes, as required under the Internal Revenue Code.
F-8
<PAGE> 32
The components of the net deferred tax amount are as follows:
December 31,
-------------------------------------
1996 1995
---------------- ----------------
Deferred tax assets $ 1,113,000 $ 1,860,000
Valuation allowance (1,113,000) (1,860,000)
---------------- ----------------
$ - $ -
================ ================
The approximate income tax effect of each type of temporary difference and
carryforward before allocation of the valuation allowance is approximately as
follows:
December 31,
-------------------------------------
1996 1995
---------------- ----------------
Operating loss and credit
carryforwards $ 1,272,000 $ 1,723,000
Temporary differences (159,000) 137,000
---------------- ----------------
$ 1,113,000 $ 1,860,000
================ ================
A valuation allowance is provided as it is more likely than not that some
portion of the deferred tax asset will not be realized. The decrease in the
valuation allowance in 1996 is primarily the result of the realization of tax
benefits for the current year's taxable income.
4. STOCK OPTIONS AND WARRANTS
Employee Stock Option Plan
Under the Company's 1989 Employee Stock Option Plan, as amended (the Plan),
3,399,000 shares of the Company's common stock have been reserved for issuance
to key employees and officers of the Company. The Plan is administered by a
committee of outside directors. Under the terms of the Plan, the Company may
grant employees either incentive stock options or non qualified stock options to
purchase shares of the Company's common stock at prices not less than fair
market value at the date of grant, as defined in the Plan. Options are
exercisable on terms to be established by the committee at its discretion.
Options are generally exercisable on a cumulative basis over the four-year
period following the date of grant and expire no later than ten years from the
date of grant.
Nonqualified Stock Options
Under the Company's 1989 Non-Qualified Stock Option Plan, as amended, 309,000
shares of the Company's common stock have been reserved for issuance to outside
(non-employee) directors. Options to purchase 25,750 shares of common stock of
the Company are automatically granted under this plan to each outside director
of the Company upon appointment to the Board of Directors ("initial options").
Initial options are exercisable on a cumulative basis over the two-year period
following the date of grant and expire no later than ten years from the date of
grant. In addition, as of March 15 of each year, options to acquire 20,600
shares are automatically granted to each person then serving as an outside
director ("annual options").
F-9
<PAGE> 33
Annual options become exercisable in full one year following the date of grant
and expire no later than ten years from date of grant. Initial options and
annual options have exercise prices equal to the fair market value on the date
of grant.
Under the Company's 1991 Non-Qualified Stock Option Plan, as amended, 309,000
shares of the Company's common stock have been reserved for issuance to key
employees and consultants. The plan is administered by a committee of the Board
of Directors. Under the terms of the plan, the Company may grant non-qualified
stock options at option prices and terms to be determined by the committee at
its discretion and expire no later than ten years from the date of grant.
Warrants
In connection with private placements in 1990 and 1991, the Company issued
warrants that entitled the holders to purchase an aggregate of 1,633,530 shares
of the Company's common stock at exercise prices that ranged from $0.94 to $1.94
per share. In 1995, 490,230 warrants were exercised at $0.94 per share, and
23,690 warrants were exercised at $1.94 per share. In 1996, 987,787 warrants
were exercised at $2.00 per share. No additional warrants remained outstanding
at December 31, 1996.
Dividends
On July 3, 1996, the Company distributed a 3% stock dividend to shareholders of
record on June 21, 1996. The shares issued in the stock dividend represented
shares which the Company acquired in the stock repurchase program. This
transaction resulted in an increase of $4,667,516 in the accumulated deficit
(633,006 shares distributed at a fair market value of $7.375 per share on June
31, 1996, the record date). Treasury stock was reduced by $2,422,730 as a result
of this distribution. Average shares outstanding and all per share amounts
included in the accompanying financial statements and Notes are based on the
increased number of shares giving retroactive effect to the stock dividend.
On December 19, 1996, the Company declared a cash dividend of $0.02 a share
payable on January 30, 1997 to holders of record at the close of business on
January 15, 1997. This cash dividend resulted in an increase of $437,221 in the
accumulated deficit and accrued dividend payable at December 31, 1996 in the
accompanying financial statements.
Accounting for Stock-Based Compensation
The Company accounts for its stock-based compensation under Accounting
Principles Board Opinion No. 25, Accounting for Stock Issued to Employees. In
October 1995, the Financial Accounting Standards Board issued SFAS No. 123,
Accounting for Stock-Based Compensation, which is effective for fiscal years
beginning after December 15, 1995. SFAS No. 123 establishes a fair-value-based
method of accounting for stock-based compensation plans. The Company has adopted
the disclosure-only alternative under SFAS No. 123, which requires the
disclosure of the pro forma effects on earnings and earnings per share as if
SFAS No. 123 had been adopted, as well as certain other information.
F-10
<PAGE> 34
The Company has computed the pro forma disclosures required under SFAS No. 123
for all stock options granted as of December 31, 1996 using the Black-Scholes
option pricing model prescribed by SFAS No. 123.
The assumptions used and the weighted average information for the years ended
December 31, 1996 and 1995 are as follows:
Years ended December 31,
------------------------
1996 1995
---- ----
Risk-free interest rates 5.36% - 6.07% 5.51% - 6.86%
Expected dividend yield 1% 1%
Expected lives 5 years 5 years
Expected volatility 84.01% 32.91%
Weighted average grant-date fair value of
options granted during the period $5.92 $3.97
Weighted-average exercise price $5.92 $3.97
Weighted-average remaining contractual
life of options outstanding 7.23 years 7.04 years
Weighted average exercise price of 1,187,616
and 2,520,436 options exercisable at
December 31, 1996 and 1995, respectively $2.45 $2.11
The total value of the options granted during 1996 and 1995 was computed as
approximately $435,000 and $774,000, respectively. Of these amounts,
approximately $210,000 and $99,000 would be charged to operations for the years
ended December 31, 1996 and 1995, respectively. The remaining amount,
approximately $900,000 would be amortized over the related vesting periods. The
pro-forma effect of SFAS No. 123 for the years ended December 31, 1996 and 1995
is as follows:
Years ended December 31,
------------------------
1996 1995
---- ----
Net income as reported $2,491,981 $1,558,686
Pro forma net income $2,281,761 $1,459,216
EPS as reported .11 .07
Pro forma net income per share .10 .06
F-11
<PAGE> 35
Because the method prescribed by SFAS No. 123 has not been applied to options
granted prior to January 1, 1995, the resulting pro forma compensation cost may
not be representative of that to be expected in future years.
A summary of all stock option and warrant transactions for the years ended
December 31, 1996, 1995 and 1994 is as follows (in thousands, except per share
amounts):
1996 1995 1994
------ ------ ------
Options and warrants at
beginning of period 3,259 3,531 8,142
Granted 265 535 136
Exercised (1,509) (800) (4,600)
Canceled (108) (7) (147)
------ ------ ------
Options and warrants outstanding at
end of period 1,907 3,259 3,531
====== ====== ======
Price range of options and warrants $ 1.85 $ 1.33 $ 0.94
outstanding at end of period to $6.22 to $6.22 to $3.64
Vested options and warrants at
end of period 1,188 2,520 2,582
5. COMMITMENTS
Lease Agreements
The Company leases certain of its facilities and equipment under operating lease
arrangements expiring on various dates through September 1998. Total minimum
lease payments, including scheduled increases, are charged to operations on a
straight-line basis over the life of the lease. Rent expense for the years ended
December 31, 1996, 1995 and 1994 was approximately $450,000, $445,000 and
$313,000, respectively.
F-12
<PAGE> 36
At December 31, 1996, minimum commitments remaining under lease agreements were
as follows:
Operating
Leases
---------
Years ending December 31:
1997 $ 299,000
1998 86,000
---------
$ 385,000
Employment Agreement
In May 1994, the Company entered into a three-year employment agreement with an
officer of the Company requiring a minimum annual salary of approximately
$116,000, subject to certain adjustments.
6. ACCRUED EXPENSES
Accrued expenses consist of the following:
December 31,
-----------------------
1996 1995
---- ----
Accrued payroll & employee benefits $ 147,615 $ 134,159
Accrued other $ 184,629 $ 60,506
--------- ---------
$ 332,244 $ 194,665
========= =========
F-13
<PAGE> 37
7. SELECTED QUARTERLY FINANCIAL DATA (Unaudited)
The following is an analysis of certain items in the accompanying statements of
income by quarter for the years ended December 31, 1996 and 1995:
<TABLE>
<CAPTION>
Income Net
from Net Income
Revenue Operations Income per Share
------- ---------- ------ ---------
1996
<S> <C> <C> <C> <C>
First Quarter $ 2,674,665 $ 388,387 $ 449,284 $ .02
Second Quarter 3,141,313 720,117 716,465 .03
Third Quarter 3,146,808 737,864 731,999 .03
Fourth Quarter 3,251,412 562,365 594,233 .03
--------------- ------------ ------------- ------
$ 12,214,198 $ 2,408,733 $ 2,491,981 $ .11
============ =========== =========== ======
1995
First Quarter $ 2,321,157 $ 338,619 $ 403,980 $ .02
Second Quarter 2,747,242 614,169 650,540 .03
Third Quarter 2,667,417 367,556 430,390 .02
Fourth Quarter 2,375,118 (19,213) 73,776 .00
--------------- --------------- --------------- ------
$ 10,110,934 $ 1,301,131 $ 1,558,686 $ .07
============ =========== =========== ======
</TABLE>
8. SUBSEQUENT EVENT
On March 4, 1997, the Company declared a cash dividend of $0.02 per share
payable on April 9,1997 to shareholders of record at the close of business on
March 20, 1997.
F-14
<PAGE> 1
Exhibit 10-8
PSYCHEMEDICS CORPORATION
1989 NON-QUALIFIED STOCK OPTION PLAN
1. STATEMENT OF PURPOSE. The purpose of this Non-Qualified Stock Option
Plan (the "Plan") is to benefit PSYCHEMEDICS CORPORATION (the "Company") through
the maintenance and development of its businesses by enabling the Company to
attract and retain well-qualified "Outside Directors" to serve on its Board by
providing a favorable opportunity to such persons to become holders of stock in
the Company over a period of years, thereby giving them a permanent stake in the
growth and prosperity of the Company and encouraging the continuance of their
involvement with the Company and/or its subsidiaries.
2. ADMINISTRATION. The Plan shall be administered by the Board of Directors
of the Company, which Board for purposes of this Plan shall be referred to as
the Committee. The Committee shall have full and plenary authority to interpret
the terms and provisions of the Plan.
3. ELIGIBILITY. Each "Outside Director" of the Company shall be eligible to
receive automatic grants of non-statutory options under this Plan (individually
an "Option" and collectively "Options") pursuant to the provisions of Section 4
hereof. A person shall be deemed an Outside Director if such person serves on
the Board of Directors and is not, at the date such service commences, an
employee of the Company or its subsidiaries. Any person who qualifies as an
Outside Director but subsequently becomes employed by the Company or its
subsidiaries shall not forfeit options granted hereunder unless such employment
commences within six (6) months of the date such person was first named a
director of the Company or any subsidiary.
4. STOCK SUBJECT TO THE PLAN. The stock issuable under this Plan shall be
shares of the Company's Common Stock, par value $.005 per share (the "Common
Stock"). Such shares may be made available from authorized but unissued shares
of Common Stock or shares of Common Stock reacquired by the Company. The
aggregate number of shares of Common Stock issuable upon exercise of Options
under this Plan shall not exceed 309,000 shares, subject to adjustment from time
to time in accordance with Section 10 hereof.
5. Automatic Grant of Options.
--------------------------
(a) INITIAL GRANT OF OPTIONS. Each individual who is initially elected or
appointed as an Outside Director on or subsequent to March 15, 1996 shall
receive, as the date of his or her initial election or appointment, an automatic
grant of an Option to purchase 25,750 shares of Common Stock.
<PAGE> 2
Subject to the provisions of Section 9 hereof, each option granted pursuant
to this Section 4(a)(herein referred to individually as an "Initial Option" and
collectively as "Initial Options") shall be for a term of ten (10) years. Each
Initial Option shall become exercisable cumulatively in twenty-four (24) equal
monthly increments of 1,072 shares (with the last such installment being for
1,094 shares), each commencing on the same numerical day of the month following
the date of automatic grant pursuant to this Section 5(a). Subject to the
foregoing, all or any part of the shares to which the right to purchase has
accrued may be purchased at the time of such accrual or at any time or times
thereafter during the option period.
(b) ANNUAL GRANT OF OPTIONS. Commencing on March 15, 1996, and continuing
in effect on the 15th day of March of each subsequent calendar year, each
individual who is at the time serving as an Outside Director shall receive an
additional automatic grant of an Option to purchase 20,600 shares of Common
Stock. Each Option granted pursuant to this Section 5(b)(herein referred to
individually as an "Annual Option" or collectively as "Annual Options") shall be
for a term of ten (10) years. Each Annual Option shall become exercisable in
full twelve (12) months following the date of automatic grant pursuant to this
Section 5(b). The Annual Option shall thereafter remain so exercisable until the
expiration or sooner termination of the Option term.
The foregoing automatic grant dates under Sections 5(a) and 5(b) are herein
referred to individually as an "Automatic Grant Date" and collectively as
"Automatic Grant Dates" and the Outside Directors receiving Options are herein
referred to individually as an "Optionee" and collectively as "Optionees."
Options granted under this Plan are not intended to be treated as incentive
stock options as defined in Section 422 of the Internal Revenue Code of 1986, as
amended (the "Code").
In the event that an option expires or is terminated or canceled
unexercised as to any shares, such released shares may again be optioned
(including a grant in substitution for a canceled option). Shares subject to
options may be made available from unissued or reacquired shares of Common
Stock.
Nothing contained in the Plan or in any option granted pursuant thereto
shall confer upon any optionee any right to be nominated by management of the
Company as a director of the Company, or interfere in any way with the right of
the Company and its Board of Directors to remove such optionee as a director of
the Company in accordance with the Company's by-laws and applicable state law.
6. EXERCISE PRICE. The price per share payable upon exercise of an Option
("Exercise Price") shall be the fair market value per share of Common Stock as
of the applicable Automatic Grant Date.
2
<PAGE> 3
For purposes of establishing the Exercise Price, the "fair market value"
shall be deemed to be the mean of the bid and asked prices of the Common Stock
at the close of the trading day next preceding the applicable Automatic Grant
Date, except that if the Common Stock is then listed on any national exchange,
fair market value shall be the mean between the high and low sales price on the
date next preceding the applicable Automatic Grant Date.
7. EXERCISE OF OPTION. An option may be exercised by giving written notice
to the Company, attention of the Secretary, specifying the number of shares to
be purchased, accompanied by the full purchase price for the shares to be
purchased either in cash or by check, or by shares of the Common Stock of the
Company, or by a combination of these methods.
At the time of exercise of any Option, the Company may, if it shall
determine it necessary or desirable for any reason, require the Optionee (or his
heirs, legatees, or legal representative, as the case may be) as a condition
upon the exercise thereof to deliver to the Company a written representation of
present intention to purchase the shares for investment and not for
distribution. In the event such representation is required to be delivered, an
appropriate legend may be placed upon each certificate delivered to the Optionee
upon his exercise of part or all of the Option and a stop transfer order may be
placed with the transfer agent. Each Option shall also be subject to the
requirement that, if at any time the Company determines, in its discretion, that
the listing, registration or qualification of the shares subject to the Option
upon any securities exchange or under any state or federal law, or the consent
or approval of any governmental regulatory body is necessary or desirable as a
condition of or in connection with, the issue or purchase of shares thereunder,
the Option may not be exercised in whole or in part unless such listing,
registration, qualification, consent or approval shall have been effected or
obtained free of any conditions not acceptable to the Company. Without limiting
any of the foregoing, no Option may be exercised until this Plan, as amended,
has been submitted to and approved by the stockholders of the Company in
accordance with law. If stockholder approval is not obtained, any options
previously granted shall be void.
8. TERMINATION OF RELATIONSHIP - EXERCISE THEREAFTER. In the event the
Optionee's service on the Board of Directors is terminated for any reason other
than death or permanent disability such optionee's option shall cease to further
vest and all rights to purchase shares which have accrued pursuant thereto shall
terminate within ten (10) days of such termination of service on said Board.
In the event of termination of said relationship because of death or
permanent disability (as that term is defined in Section 22(e)(3) of the Code,
as now in effect or as subsequently amended), the option may be exercised to the
3
<PAGE> 4
extent the option was exercisable at the date of such death or permanent
disability by the optionee or, if he is not living, by his heirs, legatees, or
legal representative, as the case may be, for a period of one (1) year after the
date of death or permanent disability, but in any event not later than ten years
after the date the option was granted.
9. NON-TRANSFERABILITY OF OPTIONS. No option shall be transferable by the
optionee otherwise than by will or the laws of descent and distribution , or
pursuant to a qualified domestic relations order as defined by the Code, or
Title I of the Employee Retirement Income Security Act of 1974, as amended
("ERISA") or the rules thereunder. Subject to the foregoing, each option shall
be exercisable during an Optionee's lifetime only by the Optionee.
10. ADJUSTMENT. The number of shares subject to the Plan and to Options
granted under the Plan shall be adjusted as follows: (a) in the event that the
outstanding shares of Common Stock of the Company is changed by any stock
dividend, stock split or combination of shares, the number of shares subject to
the Plan and to Options granted thereunder shall be proportionately adjusted;
(b) in the event of any merger, consolidation or reorganization of the Company
with any other corporation or corporations, all Options shall fully vest unless
the Committee should determine otherwise that there shall be substituted, on an
equitable basis, for each share of Common Stock then subject to the Plan,
whether or not at the time subject to outstanding Options, the number and kind
of shares of Stock or other securities to which the holders of shares of Common
Stock of the Company will be entitled pursuant to the transaction; and (c) in
the event of any other relevant change in the capitalization of the Company, the
Committee shall provide for an equitable adjustment in the number of shares of
Common Stock then subject to the Plan, whether or not then subject to
outstanding Options. In the event of any such adjustment, the purchase price per
share shall be proportionately adjusted.
11. AMENDMENT OR DISCONTINUANCE OF PLAN. This Plan may from time to time be
amended or discontinued by action of the Board of Directors or by the
stockholders of the Company; provided that: (a) any increase in the maximum
number of shares for which Options may be granted under the Plan, any change in
the method of automatic grant, or any change in the provisions relating to the
persons to whom Options shall be granted must be approved by a majority vote of
the stockholders within twelve months before or after the effective date of such
increase or change; and (b) the Board of Directors shall not have authority to
change (i) the Option prices, or (ii) the periods during which Options may be
granted or exercised, or (iii) the provisions relating to adjustments to be made
upon changes in capitalization. The termination or any modification or amendment
of the Plan shall not, without the consent of any Optionee, affect his rights
under an Option theretofore granted to him.
4
<PAGE> 5
12. EFFECTIVE DATE. The Plan was adopted by the Board of Directors and
approved by the stockholders of the Company effective September 22, 1989. The
Plan was amended and restated by the Board of Directors and approved by the
stockholders effective March 15, 1996. The number of shares set forth above as
being reserved for issuance under the Plan reflects the adjustment in such
number of shares made as a result of the stock dividend distributed by the
Company on July 3, 1996 to holders of record on June 21, 1996.
5
<PAGE> 1
EXHIBIT 11.0
CALCULATION OF SHARES USED IN DETERMINING NET INCOME PER COMMON SHARE(1)
Years Ended December 31,
------------------------
1996 1995 1994
---- ---- ----
Weighted average common stock
outstanding during the period 21,212,080 21,944,116 18,441,389
Weighted average common stock
equivalents 952,146 1,459,942 1,480,225
---------- ---------- ----------
22,164,226 23,404,058 19,921,614
========== ========== ==========
(1) Fully diluted net income per share has not been separately presented, as
the amount would not be materially different from primary net income per
share.
<PAGE> 1
CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS
As independent public accountants, we hereby consent to the incorporation of our
report included in this Form 10-K into the Company's previously filed
Registration Statements File Nos. 33-41787, 33-50712, 33-45332, 33-66942,
33-58970 and 333-12403.
ARTHUR ANDERSEN LLP
Boston, Massachusetts
March 28, 1997
<TABLE> <S> <C>
<ARTICLE> 5
<MULTIPLIER> 1
<CURRENCY> US DOLLARS
<S> <C>
<PERIOD-TYPE> YEAR
<FISCAL-YEAR-END> DEC-31-1996
<PERIOD-START> JAN-01-1996
<PERIOD-END> DEC-31-1996
<EXCHANGE-RATE> 1
<CASH> 1,462,678
<SECURITIES> 8,370,727
<RECEIVABLES> 2,657,416
<ALLOWANCES> 0
<INVENTORY> 230,777
<CURRENT-ASSETS> 12,851,426
<PP&E> 4,843,412
<DEPRECIATION> 2,399,919
<TOTAL-ASSETS> 15,744,520
<CURRENT-LIABILITIES> 1,448,703
<BONDS> 0
108,790
0
<COMMON> 0
<OTHER-SE> 14,187,127
<TOTAL-LIABILITY-AND-EQUITY> 15,744,520
<SALES> 12,214,198
<TOTAL-REVENUES> 12,214,198
<CGS> 4,981,221
<TOTAL-COSTS> 0
<OTHER-EXPENSES> 4,824,244
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> 2,768,981
<INCOME-TAX> 277,000
<INCOME-CONTINUING> 2,408,733
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 2,491,981
<EPS-PRIMARY> 0.11
<EPS-DILUTED> 0.11
</TABLE>
